| Study: | Phase III Parkinson’s disease study with more than 870 participants at 102 sites in the US and Canada. |
| Services Provided: | All the services normally associated with a large, Phase III study. |
| Challenges: | To take over part of the project from another CRO. PharmaNet started with 26 sites enrolling 231 participants, which then increased to 102 sites enrolling 870 participants.
Ten months after PharmaNet took over the entire study, the client asked for a previously unplanned interim analysis of the project. |
| Solutions: | The PharmaNet Neuroscience team worked diligently with sites to ensure a smooth transition from the original CRO on site files, Investigator payments, and many other issues. |
| Outcome: | The interim analysis was expertly handled and assured the client to continue the program.
The program resulted in an NDA submission. |
 |
||
 |
In Phase II-IV PharmaNet offers all the clinical development services traditionally associated with conducting Phase II-IV programs. A key differentiating factor of PharmaNet is that in every program we conduct, PharmaNet provides an unrivaled combination of experienced project-management teams, senior management oversight, and an exclusive approach to building relationships with sponsors. |
 |
 |
||
Parkinson’s Disease, Phase III
PharmaNet Development Group, Inc.
504 Carnegie Center, Princeton, NJ 08540Tel 609 951 6800Fax 609 514 0390
504 Carnegie Center, Princeton, NJ 08540Tel 609 951 6800Fax 609 514 0390
© 2008 PharmaNet Development Group, Inc. All rights reserved.